Schering-Plough (SGP) Announces Changes to its Global Collaboration with Novartis (NVS)
More News related to NVS
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
- Hapoalim Securities Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Ongoing Programs to Help Drive Share Price
- Novartis Champions Renewable Energy With New Vacaville Solar Array
- Trading Radar for 10/22: AT&T (T), McDonalds (MCD), Amazon.com (AMZN), 3M (MMM), Dow Chemical (DOW), UPS (UPS) Report
More News related to SGP
- "AIM"ING FOR BETTER ASTHMA CARE
- Merck and Schering-Plough to Complete Merger Today
- Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
- Schering-Plough Announces Sponsorship of Rabies-Control Projects in India
- Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
Schering-Plough Corporation (NYSE: SGP) announced changes to its global collaboration with Novartis (NYSE: NVS) for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The changes will result in Schering-Plough assuming exclusive worldwide rights to develop and commercialize a fixed-dose combination of its inhaled corticosteroid ASMANEX(R) (mometasone furoate inhalation powder), and Novartis' long-acting beta2-adrenergic receptor agonist, FORADIL(R) (formoterol fumarate). Also as a result, Novartis will assume exclusive worldwide rights to develop and commercialize a fixed-dose combination of Schering-Plough's inhaled corticosteroid mometasone furoate with its investigational beta2-agonist QAB149 (indacaterol).
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.22Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
